alexa Pharmaceutical Care Era: The Rise Of Medication Therapy Management | 13251
ISSN: 2167-065X

Clinical Pharmacology & Biopharmaceutics
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Recommended Conferences

33rd World Congress on Pharmacology

Barcelona, Spain
Share This Page

Pharmaceutical care era: The rise of medication therapy management

International Summit on Clinical Pharmacy & Dispensing

Ayman M. Noreddin

Keynote: Clinic Pharmacol Biopharmaceut

DOI: 10.4172/2167-065X.S1.001

Abstract
Medication therapy, the most widely used intervention in healthcare, is increasingly becoming more complex. Patients are seeing multiple caregivers and are using multiple medications, both prescription and over-the- counter. This has led thousands to suffer from medication-related problems that are costing billions of dollars. In response to this growing problem the profession of Pharmacy has responded by offering Medication Therapy Management (MTM) services. MTM is a collaborative effort between a healthcare professional and a patient, which is designed to promote safe and effective medication use and help the patient achieve optimal outcomes from their medication therapy. In order to meet the patient?s drug-related needs the new role of the pharmacist is to ensures that all drug therapy is appropriate for each medical condition, the patient?s drug therapy is the most effective available and safest possible, and the patient is able to take the medication as intended. Additionally, the least expensive but effective drug product is always considered as part of cost containment.
Biography
Noreddin received his Ph.D. in Pharmaceutical Sciences from the University of the Pacific, California and received research training as a visiting scholar at the Department of Medicine, Stanford University. He had postdoctoral fellowship (Pharmacokinetics and Pharmacodynamics of Antimicrobials), Department of Medical Microbiology, University of Manitoba followed by an American College of Clinical Pharmacy postdoctoral fellowship (Infectious Diseases). Dr. Noreddin?s research interest includes Pharmacoklinetic/ Pharmacodynamic modeling of anti-infective and anti-cancer therapy, clinical simulation and Monte Carlo analysis and bacterial resistance in biofilm studies. Dr. Noreddin has outstanding records of scientific and academic accomplishments with multiple research funding, numerous publications in highly prestigious journals and various presentations in both national and international conferences. He served as a scientific reviewer for the NIH as well as other national and international research institutions.
Top